Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
Both studies achieved the primary and key secondary endpoints, with significant improvements observed as early as week 1.
Optimistic Investors Push Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Up 30% But Growth Is Lacking
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shareholders are no doubt pleased to see that the share price has bounced 30% in the last month, although it is still struggling to make up recently lost
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Mizuho Securities analyst Uy Ear maintains $Arcutis Biotherapeutics(ARQT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.3% and a total average return of 6.3%
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
TD Cowen analyst Tyler Van Buren maintains $Arcutis Biotherapeutics(ARQT.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 44.
Arcutis Biotherapeutics (ARQT) Gets a Buy From TD Cowen
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Needham analyst Serge Belanger maintains $Arcutis Biotherapeutics(ARQT.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 41.4%
Express News | Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $18 Price Target
Arcutis Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 74.76% Needham $18 → $18 Reiterates Buy → Buy 05/15/2024 74.76% Needham $16 → $18 Maintains
Buy Rating Affirmed for Arcutis Biotherapeutics Following FDA Approval of Zoryve for Atopic Dermatitis
Express News | Arcutis Biotherapeutics Shares up 5.3% Premarket After FDA Approves Expanded Use of Co's Skin Disease Drug
Trending Stocks Today: VivoPower Shoots up 21.17% Post-Market
July 9th - US stocks trending post-market.Gainers: $VivoPower(VVPR.US)$ shoots up 21.17% to $3.09 with a turnover of $9.42 million. $Pineapple Energy(PEGY.US)$ climbs 6.08% to $2.44 with a turnover
Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA
By Sabela Ojea Arcutis Biotherapeutics said the U.S. Food and Administration has approved its supplemental new drug application for Zoryve cream to treat mild to moderate atopic dermatitis. The
Express News | Trading Halt: Halt Status Updated at 5:15:00 PM ET: Quotation Resumption: News and Resumption Times
Arcutis Gets FDA Approval for Zoryve for Atopic Dermatitis
Express News | Arcutis Biotherapeutics Inc - Commercial Product Expected to Be Available by End of July
Express News | FDA Approves Arcutis’ Zoryve® (Roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Trading Halt: Halted at 4:25:38 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 4:25:38 P.m. ET - Trading Halt: Halt News
Express News | Arcutis Biotherapeutics: FDA Indicated That They Are Working to Finalize Action Letter & Have Not Indicated They Would Extend Pdufa Goal Date of Jul 7
Express News | Arcutis Biotherapeutics: Has Been in Communication With U.s FDA . Regarding Its Supplemental New Drug Application (Snda) for Roflumilast Cream 0.15%